Diagnostic News and Research

RSS

BARDA awards $4.2 million contract to Menssana Research to develop breath test for radiation exposure

The Biomedical Advanced Research and Development Authority in the US Department of Health and Human Services has awarded Menssana Research Inc., a company with research facilities in the NJIT Enterprise Development Center, a contract for $4.2 million to develop a breath test for radiation exposure. If the contract is exercised with options, it could total $22.84 million.

11 Oct 2010

Roche, DKFZ announce research collaboration to predict cervical cancer risk

Roche Molecular Systems, Inc. and the German Cancer Research Center announced today that they have entered into a research collaboration to enable more specific prediction of a woman's risk for developing cervical cancer.

From Roche Sequencing and Life Science 11 Oct 2010

Research reveals that fragrances can cause contact allergy

The fragrances used in many household and skincare products can cause contact allergy when exposed to oxygen in the air, reveals research from the University of Gothenburg's Faculty of Science in conjunction with the University of Gothenburg to be presented at the dermatologist conference in Gothenburg.

11 Oct 2010

Researchers determine genetic structures of bacteria that cause Lyme disease

Researchers Dr. Steven E. Schutzer of UMDNJ-New Jersey Medical School and Dr. Claire M. Fraser-Liggett of the Institute for Genome Sciences, University of Maryland, and their collaborators have made a major achievement toward better understanding Lyme disease, by determining the complete genetic structures of 13 strains of the bacteria that cause the disease.

11 Oct 2010

UBM Medica presents virtual conference for radiologists, imaging professionals

UBM Medica presented Diagnostic Imaging LIVE, a virtual conference for radiologists and imaging professionals, on September 29, 2010.

8 Oct 2010

Experts meet on ESMO Congress to bring new hope to cancer patients

"A congress of records," is how Professor David J. Kerr, President of the European Society for Medical Oncology described the 35th ESMO Congress, at the opening press conference for the biggest medical oncology event in Europe. "We have had record numbers of submitted and accepted abstracts and are expecting a record number of attendees." The ESMO meeting brings together cancer specialists, patients, industry representatives and members of the media. The 35th ESMO Congress takes place at Fiera Milano City, in Milan, Italy, from 8 to 12 October 2010.

8 Oct 2010

Presbyterian Hospital collaborates with New York Center for Autism to establish Institute for Brain Development

NewYork-Presbyterian Hospital, along with its affiliated medical schools Columbia University College of Physicians and Surgeons and Weill Cornell Medical College, announced its collaboration with the New York Center for Autism to establish the Institute for Brain Development, a comprehensive, state-of-the-art institute dedicated to addressing the pressing clinical needs of individuals living with autism spectrum disorders and other developmental disorders of the brain, across their lifespan.

8 Oct 2010

GE Healthcare announces successful completion of vendor neutral DI-r

GE Healthcare announced today the successful completion of a vendor neutral Digital Imaging Repository that connects hospitals and medical centers throughout Southwestern Ontario, Canada, enabling the sharing of patient health data across the region. For the first time in Ontario's history, 26 hospital organizations in the Erie St. Clair and South West Local Health Integration Networks are able to share filmless diagnostic image exams between their facilities.

8 Oct 2010

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections.

8 Oct 2010

New imaging technique may help in early detection of prostate cancer

Prostate cancer -- the most common cancer afflicting American men -- may be effectively diagnosed at an early stage without ionizing radiation, using a non-invasive imaging technique known as contrast-enhanced ultrasound (CEUS), according to a report announced late last week at the 25th Annual Advances in Contrast Ultrasound - ICUS Bubble Conference in Chicago.

8 Oct 2010

Biomoda extends pilot clinical trial of CyPath assay for early-stage lung cancer detection

Cancer diagnostics company Biomoda, Inc. today announced in its new monthly President's Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.

8 Oct 2010

New Bioactive technology can be applied in rapid diagnostics tests

VTT printed the paper with antibodies that react to the sample. The test result can be read in the form of a line, for example, which either does or does not appear depending on the sample - just like in the pregnancy tests already familiar to consumers. It is also possible to print instructional images or text, for example, either on or alongside the test.

8 Oct 2010

Cepheid collaborates with Novartis to commercialize BCR-ABL monitoring test

Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management.

7 Oct 2010

Should Medicare consider cost-effectiveness when setting reimbursement rates?

Medicare reimbursement rates should be based on how cost effective the treatment is for a particular illness, according to a piece by two policy experts in the October edition of Health Affairs.

7 Oct 2010

Caris Target Now molecular tumor profiling increases PFS in cancer patients

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from a multi-center, prospective, pilot study published in the Journal of Clinical Oncology.

7 Oct 2010

Louise A. Villejo recognized with 2010 Julie and Ben Rogers Award for Excellence in Education

Louise A. Villejo, executive director of the Patient Education Office at The University of Texas MD Anderson Cancer Center, is the recipient of the 2010 Julie and Ben Rogers Award for Excellence in Education.

7 Oct 2010

Neoprobe completes pre-NDA assessment for Lymphoseek with FDA

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a pre-NDA assessment for Lymphoseek with the U.S. Food and Drug Administration (FDA).

7 Oct 2010

ESH and ERS consent document to manage hypertension and OSA

Consensus document on the management of patients with obstructive sleep apnea and hypertension. Joint recommendations by The European COST Action B26, The European Society of Hypertension and The European Respiratory Society.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Scientists develop first screening method to identify river blindness disease

Scientists from The Scripps Research Institute have developed the first screening method that rapidly identifies individuals with active river blindness, a parasitic disease that afflicts an estimated 37 million people. The test could change the current strategy of mass treatment in areas where river blindness, also known as onchocerciasis, is suspected.

7 Oct 2010